Cytomedix Live Presentation at Lippert/Heilshorn & Associates, Inc. Life Sciences & Medical Technologies Virtual Conference - July 20, 2010 at 9:00 a.m. ET. Download/Print a PDF document regarding this presentation.

Sixth Annual Noble Financial Equity Conference - Tuesday, June 8, 2010 at 1:30 p.m. ET

Cytomedix To Host First Quarter 2010 Financial Results Conference Call On Tuesday, May 18, 2010

Webcast Presentation - Q4 2009 Cytomedix Earnings Conference Call - Tuesday, March 30, 2010 10:00 a.m. ET

A replay of the conference call will be accessible two hours after its completion through April 6, 2010 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 64458581.  Read the full press release.

Webcast Presentation - Q3 2009 Cytomedix Earnings Conference Call - Thursday, November 12, 2009 10:00 a.m. ET

Webcast Presentation - Cytomedix at The 8th Annual BIO Investor Forum - Thursday, October 29 2:30 PM PT

Webcast Presentation - Martin Rosendale will be presenting a corporate update at Security Research Associates’
Growth Stock Conference on Monday, October 19th at 4:00 p.m. (Eastern Time).  The webcast will be archived for 90 days.

Investor Presentation – June 2009
“Martin Rosendale, Cytomedix CEO, was recently a featured guest on the Leaders Spot with Rebecca Blacksmith. During the interview Mr. Rosendale discusses his leadership styles and philosophies for leading Cytomedix, as well as the challenges and successes of the AutoloGel System” To listen to the full interview click on the link.
Cytomedix Rodman & Renshaw webcast presentation - 11/12/2008 - 2:25 PM ET



 

Quick Viewing Tips
If you don't have Microsoft PowerPoint on your computer, you can download a free PowerPoint viewer which will allow you to view the presentations here.

Statements contained in these communications not relating to historical factsare forward-looking statements that are intended to fall within the safeharbor rule under the Private Securities Litigation Reform Act of 1995. The information contained in the forward looking statements is inherentlyuncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability topredict or control, including among others, uncertainty of research andtesting results, governmental decisions and regulation, acceptance by the medical community, competition, and overall economic conditions. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix.

For more information email investorrelations@cytomedix.com